Solid tumors after chronic lymphocytic leukemia

Hisada, M Biggar, RJ Greene, MH Fraument, JF Travis, LB

M. Hisada et al., Solid tumors after chronic lymphocytic leukemia, BLOOD, 98(6), 2001, pp. 1979-1981

23

INGLESE

Article

Hematology,"Cardiovascular & Hematology Research

BLOOD

0006-4971 → ACNP

98

6

2001

1979 - 1981

ISI

0006-4971(20010915)98:6<1979:STACLL>2.0.ZU;2-O

Prior reports indicate that patients with chronic lymphocytic leukemia (CLL ) may be at increased risk of subsequent neoplasms. This study quantified t he risk of second cancers among 16 367 patients with CLL in the population- based Surveillance, Epidemiology and End Results Program. Overall, the obse rved/expected ratio (O/E) was 1.20 (95% confidence Interval [CI], 1.15-1.26 ). Second cancer risks for patients who received chemotherapy only as the f irst course of treatment (O/E = 1.21) were similar to risks for those who r eceived no treatment initially (O/E = 1.19). Significant excesses were foun d for Kaposi sarcoma (O/E = 5.09), malignant melanoma (O/E = 3.18), and can cers of the larynx (O/E = 1.72) and the lung (O/E = 1.66). Increased risks were also found for brain cancer among men (O/E = 1.91) and for cancers of the stomach (O/E = 1.76) and bladder (O/E = 1.52) among women. Additional i nvestigations of cancers after CLL are needed to explore the role of immuno logic impairment and/or other etiologic influences.